ReviewJournal of bone and mineral metabolism2026
Marrow fatty acids in osteoporosis: metabolic insights, emerging therapeutic targets.
Review in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis review examines the role of marrow adipose tissue fatty acid composition in skeletal homeostasis, focusing on osteoporosis. To avoid conceptual confusion, we define evidence tiers: human studies assessing endogenous marrow lipid profiles; mechanistic studies applying exogenous fatty acids in vitro and in vivo; indirect MRI-based surrogates of marrow fat quantity; and direct ex vivo measurements of fatty acid composition via GC-MS, LC-MS, and lipidomics. We also clarify the distinction between marrow fat quantity and fatty acid quality.
resultHuman data reveal disease-, age-, and site-related alterations in marrow lipid saturation and unsaturation; however, findings vary by skeletal site, marrow compartment, fracture status, analytical platform, and study population. Experimental evidence demonstrates that saturated fatty acids (e.g., palmitic acid) induce lipotoxicity and osteoblast dysfunction, whereas unsaturated fatty acids (e.g., oleic acid and n-3 polyunsaturated fatty acids) exert protective effects via modulation of mesenchymal stem cell differentiation, osteoclastogenesis, ferroptosis, autophagy, and mitochondrial metabolism. Collectively, current evidence supports an association between marrow fatty acid biology and osteoporotic bone loss.
conclusionCausal, diagnostic, and therapeutic implications remain preliminary. This review's main contribution is a fatty-acid-centered framework that integrates evidence tiers, molecular categories, and skeletal-site heterogeneity, guiding future research.
Indexed as
Identifiers
42295423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.